Transcatheter tricuspid valve replacement (TTVR) with the EVOQUE system led to substantial quality of life improvements for severe tricuspid regurgitation (TR) patients versus optimal medical therapy (OMT) alone, according to a new 1-year analysis of the TRISCEND II pivotal trial.